Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2017-10-05 Investor Presentation
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Presentation to Investors 15 pages 3.1MB
Investor Presentation Classification · 95% confidence The document is a presentation titled 'Investor Update October 2017' by Biotron Limited, addressed to the ASX and investors. It contains detailed information about the company's business, pipeline, clinical trials, and investment highlights. The text mentions a PowerPoint presentation by the Managing Director and includes forward-looking statements, clinical trial progress, and commercialisation plans. There are no financial statements or detailed financial data typical of annual or interim reports. The document is a presentation aimed at investors, focusing on company strategy, pipeline, and milestones. Therefore, it fits the category of an Investor Presentation (IP). The document length (8335 characters) supports it being a full presentation rather than a brief announcement or regulatory filing.
2017-10-05 English
Appendix 4G and Corporate Governance Statement 20 pages 201.6KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and is related to the 'Key to Disclosures Corporate Governance Council Principles and Recommendations' for Biotron Ltd for the financial year ended 30 June 2017. It references ASX Listing Rules 4.7.3 and 4.10.3, which require entities to lodge a corporate governance statement with the ASX at the same time as their annual report. The document contains detailed disclosures about the company's adherence to corporate governance principles and recommendations, including board structure, roles, diversity policies, and evaluation processes. It is not the annual report itself but a governance disclosure document related to the annual report. The content aligns with governance information rather than financial results, audit, or other categories. Therefore, the document fits best under the category 'Governance Information' (CGR). The document length (15,000 characters) and detailed content confirm it is a substantive governance disclosure, not a brief announcement or certification.
2017-08-27 English
Full Year Statutory Accounts 53 pages 586.4KB
Annual Report Classification · 100% confidence The document is a detailed report titled 'Annual Report for the year ended 30 June 2017' from Biotron Limited. It includes comprehensive financial data, operating and financial review, corporate governance statement, directors' report, auditor's report, and detailed notes to the financial statements. The presence of an Appendix 4E Preliminary Final Report and the mention of audited year-end accounts further confirm this is a full annual report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K).
2017-08-27 English
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited 2 pages 38.7KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 27 July 2017 from Biotron Limited to the ASX Limited. It informs that the Phase 2 HIV-1 clinical trial (BIT225-009) is fully recruited and provides details about the trial progress and next steps. The document is only 3853 characters long, which is relatively short and does not contain any financial statements, detailed financial data, or comprehensive analysis. It is primarily a progress update on a clinical trial, not a financial report or regulatory filing. There is no indication that this is a full annual or interim report, audit report, earnings release, or any other detailed financial or governance document. It is also not a voting result, capital update, or legal proceeding. Given the length and content, this fits best as a Regulatory Filing (RNS) which is a general category for miscellaneous announcements that do not fit other specific categories.
2017-07-26 English
Appendix 3B 9 pages 95.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities' and references ASX Listing Rules 3.10 and related rules. It details the issuance of 2,444 fully paid ordinary shares upon exercise of options, including terms, issue price, and quotation application. The document is a formal announcement to the ASX regarding new securities issued and their quotation, consistent with regulatory requirements for capital changes. It does not contain financial statements, management discussion, or earnings data, nor is it a report or presentation. The content aligns with announcements about new share issues and capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief report publication announcement or a regulatory filing fallback. Confidence is high due to clear identification of the document type and content.
2017-07-18 English
Appendix 4C - quarterly 5 pages 91.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated cash flow statements for the current quarter and year to date, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The content is consistent with a quarterly financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. The document length is 8177 characters, which is sufficient to be a full report rather than a brief announcement. The presence of detailed cash flow data and compliance statements aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the appropriate classification is IR with high confidence.
2017-07-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.